An open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens (ACROBAT EDGE)
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs CRN-00808 (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms ACROBAT EDGE
- Sponsors Crinetics Pharmaceuticals
- 19 Mar 2019 According to a Crinetics Pharmaceuticals media release, the first patient has been dosed in this trial.
- 23 Nov 2018 New trial record
- 13 Nov 2018 According to a Crinetics Pharmaceuticals media release, this trial is expected to begin in early 2019.